Pharmacokinetics (PK) of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (AlloSCT) recipients are associated with significantly higher clearance

被引:0
|
作者
Militano, O
Roache, K
Shaw, LM
Figurski, M
Satwani, P
Ayello, J
Wolownik, K
Foley, S
Hawkes, R
Del Toro, G
Bradley, MB
George, D
Garvin, J
Bhatia, M
Roman, L
Cairo, MS
机构
[1] New York Presbyterian, New York, NY USA
[2] Columbia Univ, New York, NY USA
[3] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1823
引用
收藏
页码:518A / 518A
页数:1
相关论文
共 50 条
  • [31] Clinically "silent" weight loss associated with mycophenolate mofetil in pediatric renal transplant recipients
    Laskin, Benjamin
    Goebel, Jens
    PEDIATRIC TRANSPLANTATION, 2008, 12 (01) : 113 - 116
  • [32] Long-term pharmacokinetics of mycophenolate mofetil (MF) suspension in pediatric renal transplant recipients.
    Weber, LT
    Hoecker, B
    Bunchman, T
    Rashford, M
    Toenshoff, B
    PEDIATRIC TRANSPLANTATION, 2005, 9 : 66 - 66
  • [33] Long-term pharmacokinetics of mycophenolate mofetil (MMF) suspension in pediatric renal transplant recipients: 3-year results from the prospective tricontinental trial
    Weber, LT
    Hoecker, B
    Bunchman, T
    Rashford, M
    Toenshoff, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 402 - 402
  • [34] Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients
    Keiji Kurata
    Kimikazu Yakushijin
    Atsuo Okamura
    Motohiro Yamamori
    Hiroya Ichikawa
    Rina Sakai
    Yu Mizutani
    Seiji Kakiuchi
    Yoshiharu Miyata
    Akihito Kitao
    Shinichiro Kawamoto
    Hiroshi Matsuoka
    Tohru Murayama
    Hironobu Minami
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 839 - 846
  • [35] Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients
    Kurata, Keiji
    Yakushijin, Kimikazu
    Okamura, Atsuo
    Yamamori, Motohiro
    Ichikawa, Hiroya
    Sakai, Rina
    Mizutani, Yu
    Kakiuchi, Seiji
    Miyata, Yoshiharu
    Kitao, Akihito
    Kawamoto, Shinichiro
    Matsuoka, Hiroshi
    Murayama, Tohru
    Minami, Hironobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 839 - 846
  • [36] Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients
    Labriffe, Marc
    Vaidie, Julien
    Monchaud, Caroline
    Debord, Jean
    Turlure, Pascal
    Girault, Stephane
    Marquet, Pierre
    Woillard, Jean-Baptiste
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (08) : 1550 - 1559
  • [37] Transplant associated microangiopathy in recipients of allogeneic stem cell transplants
    Martinez, M
    Bucher, C
    Stuessi, G
    Heim, D
    Buser, A
    Tsakiris, D
    Tichelli, A
    Gratwohl, A
    Passweg, J
    BONE MARROW TRANSPLANTATION, 2005, 35 : S130 - S130
  • [38] PROCALCITONIN IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) RECIPIENTS
    Watson, T. M.
    Fry, T. J.
    Jacobsohn, D. A.
    Sande, J.
    Yates, B.
    Stevenson, A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S268 - S268
  • [39] PHARMACODYNAMIC PREDICTION OF GVHD RISK IN REDUCED-INTENSITY CONDITIONING REGIMEN ALLOGENEIC STEM CELL TRANSPLANTATION (RIC ALLOSCT) USING MYCOPHENOLATE MOFETIL (MMF) PLUS CYCLOSPORINE A (CSA) AS GVHD PROPHYLAXIS
    Martinez, C.
    Millan, O.
    Rovira, M.
    Fernandez-Aviles, F.
    Suarez-Lledo, M.
    Urbano-Ispizua, A.
    Brunet, M.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S283 - S283
  • [40] ADENOVIRUS (ADV) INFECTION IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) RECIPIENTS IS A MAJOR INDEPENDENT FACTOR FOR SIGNIFICANTLY INCREASING THE RISK OF TREATMENT RELATED MORTALITY
    El-Mallawany, N. K.
    George, D.
    Jin, Z.
    Della-Latta, P.
    Satwani, P.
    Garvin, J. H.
    Bradley, M. B.
    Bhatia, M.
    van de Ven, C.
    Morris, E.
    Schwartz, J.
    Cairo, M. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S258 - S258